Zobrazeno 1 - 10
of 32
pro vyhledávání: '"Inyoung Baek"'
Autor:
Josef S. Smolen, Young Mo Kang, Wan-Hee Yoo, Paul Emery, Michael E. Weinblatt, Edward C. Keystone, Mark C. Genovese, Gihyun Myung, Inyoung Baek, Jeehoon Ghil
Publikováno v:
Arthritis Research & Therapy, Vol 22, Iss 1, Pp 1-9 (2020)
Abstract Objective Phase III clinical trials of the tumour necrosis factor inhibitors SB4, SB2, and SB5 (biosimilars to etanercept, infliximab, and adalimumab, respectively) have demonstrated efficacy in moderate-to-severe rheumatoid arthritis (RA).
Externí odkaz:
https://doaj.org/article/078e3fc0c86e4ce59dfa6b3cf0caed92
Autor:
Edward Keystone, Josef S Smolen, Paul Emery, Mark C Genovese, Michael E Weinblatt, Jung-Yoon Choe, Gihyun Myung, Evelyn Hong, Inyoung Baek, Jeehoon Ghil
Publikováno v:
RMD Open, Vol 6, Iss 1 (2020)
Objective To evaluate the relationship between disease activity and radiographic progression in rheumatoid arthritis, three phase III studies of SB4, SB2 and SB5 (biosimilars of etanercept, infliximab and adalimumab) were pooled to assess radiographi
Externí odkaz:
https://doaj.org/article/30209bb8dd3342e69b51648034291511
Autor:
Bohdana Ratitch, Siying Li, Guochen Song, Russell Reeve, Ilya Lipkovich, Shein-Chung Chow, Jonathan Kay, Martha Behnke, Aijing Zhang, Inyoung Baek, Michael O'Kelly
Publikováno v:
Statistics in Biopharmaceutical Research. 14:204-216
Because of structural complexity, a “biosimilar” will not be exactly the same as its reference biologic treatment, but is required to be equivalent in all relevant attributes, including efficacy. T...
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::a477ff6cc06e1bb1ecc354ad49a67cf5
https://doi.org/10.1080/19466315.2020.1832567
https://doi.org/10.1080/19466315.2020.1832567
Autor:
Young Mo Kang, Michael E. Weinblatt, Gihyun Myung, Wan-Hee Yoo, Josef S Smolen, Inyoung Baek, Edward C. Keystone, Jeehoon Ghil, Paul Emery, Mark C. Genovese
Publikováno v:
Arthritis Research & Therapy, Vol 22, Iss 1, Pp 1-9 (2020)
Arthritis Research & Therapy
Arthritis Research & Therapy
Objective Phase III clinical trials of the tumour necrosis factor inhibitors SB4, SB2, and SB5 (biosimilars to etanercept, infliximab, and adalimumab, respectively) have demonstrated efficacy in moderate-to-severe rheumatoid arthritis (RA). Data from
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7a1be6f6ecb1a9252374bc497a2ed1b3
http://link.springer.com/article/10.1186/s13075-020-02267-z
http://link.springer.com/article/10.1186/s13075-020-02267-z
Autor:
Mee So Lee, Gyeong-Moon Kim, Ingyeong Kim, Jae-Hwan Kim, Hyungjun Kim, Inyoung Baek, Ye Sel Kim, Oh Young Bang
Publikováno v:
Stroke. 51
Introduction: The Ring Finger Protein213 ( RNF213 ) gene variant is a relatively common variant in general population of East Asian countries (0.43 to 1.8%). Recently, RNF213 is reportedly a susceptibility gene not only for moyamoya disease (MMD) but
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::f6276ee1a46adb83caea07c5059789bc
https://doi.org/10.1161/str.51.suppl_1.wp271
https://doi.org/10.1161/str.51.suppl_1.wp271
Autor:
Mee So Lee, Inyoung Baek, Gyeong-Moon Kim, Jae-Hwan Kim, Ye Sel Kim, Oh Young Bang, Hyungjun Kim, Ingyeong Kim
Publikováno v:
Stroke. 51
Background: Although pathogenic mechanisms of moyamoya disease remain unknown, recent studies suggest that it is a caveolae disease. This study evaluated the effect of udenafil, a phosphodiesterase-5 inhibitor, on vessel maturation in in vitro and in
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::5d0340562157e3cf2a51ac8b7735b5d7
https://doi.org/10.1161/str.51.suppl_1.tp475
https://doi.org/10.1161/str.51.suppl_1.tp475
Autor:
Oh Young Bang, Inyoung Baek, Jae-Hwan Kim, Hyungjun Kim, Ingyeong Kim, Mee So Lee, Gyeong-Moon Kim, Ye Sel Kim
Publikováno v:
Stroke. 51
Introduction: Intracranial large arterial disease (ILAD) is common, especially in Asians. We compared clinical, genetic, and imaging features between symptomatic and asymptomatic ILAD. Methods: We conducted a prospective study of patients with acute
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::97fbfd75fcd9bdae622686532e230a56
https://doi.org/10.1161/str.51.suppl_1.wp270
https://doi.org/10.1161/str.51.suppl_1.wp270
Autor:
Smolen, Josef S., Kang, Young Mo, Wan-Hee Yoo, Emery, Paul, Weinblatt, Michael E., Keystone, Edward C., Genovese, Mark C., Gihyun Myung, Inyoung Baek, Jeehoon Ghil
Additional file 1 : Table S1. Disease activity cut-off values. Fig. S1A. Predicted probability (with 95% confidence limits) of patients with radiographic progression (yes/no) based on CDAI. B. Predicted probability (with 95% confidence limits) of pat
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1955e25ff1ecddcae13a57839f93f08f
Autor:
Margarita Pileckyte, Asta Baranauskaite, Eva Dokoupilova, Michael E. Weinblatt, Agnieszka Zielińska, Artur Racewicz, Krystyna Jedrychowicz-Rosiak, Jeehoon Ghil, Inyoung Baek, Janusz Jaworski
Publikováno v:
Arthritis & Rheumatology. 70:832-840
Objective The 24-week equivalent efficacy and comparable safety results of the biosimilar SB5 and reference adalimumab (ADA) from the phase III randomized study in patients with moderate-to-severe rheumatoid arthritis (RA) have been reported previous
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b42d84a65e8749094a4cee9ee604336e
https://doi.org/10.1002/art.40444
https://doi.org/10.1002/art.40444
Autor:
Smolen, Josef S., Young Mo Kang, Wan-Hee Yoo, Emery, Paul, Weinblatt, Michael E., Keystone, Edward C., Genovese, Mark C., Gihyun Myung, Inyoung Baek, Ghil, Jeehoon
Publikováno v:
Arthritis Research & Therapy; 8/14/2020, Vol. 22, p1-9, 9p